Nicholas Mikolajewicz, Patricia P Yee, Debarati Bhanja, Mara Trifoi, Alexandra M Miller, Philippe Metellus, Stephen J Bagley, Leonora Balaj, Leonardo J M de Macedo Filho, Brad E Zacharia, Dawit Aregawi, Michael Glantz, Michael Weller, Manmeet S Ahluwalia, Thomas Kislinger, Alireza Mansouri
Effective diagnosis, prognostication, and management of CNS malignancies traditionally involves invasive brain biopsies that pose significant risk to the patient. Sampling and molecular profiling of cerebrospinal fluid (CSF) is a safer, rapid, and noninvasive alternative that offers a snapshot of the intracranial milieu while overcoming the challenge of sampling error that plagues conventional brain biopsy. Although numerous biomarkers have been identified, translational challenges remain, and standardization of protocols is necessary...
April 12, 2024: Journal of Clinical Oncology